QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:CGTX

Cognition Therapeutics (CGTX) Stock Price, News & Analysis

$1.88
+0.06 (+3.30%)
(As of 04:37 PM ET)
Today's Range
$1.78
$1.88
50-Day Range
$1.78
$2.53
52-Week Range
$0.90
$3.49
Volume
187,320 shs
Average Volume
214,913 shs
Market Capitalization
$73.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Cognition Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
316.7% Upside
$7.50 Price Target
Short Interest
Healthy
1.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.02mentions of Cognition Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$9,975 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.10) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

377th out of 939 stocks

Biological Products, Except Diagnostic Industry

54th out of 154 stocks

CGTX stock logo

About Cognition Therapeutics Stock (NASDAQ:CGTX)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CGTX Stock Price History

CGTX Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
A Preview Of Cognition Therapeutics's Earnings
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Cognition Therapeutics Inc CGTX
See More Headlines
Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGTX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.67
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+298.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-21,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.39 per share

Miscellaneous

Free Float
29,718,000
Market Cap
$73.32 million
Optionable
Not Optionable
Beta
1.67
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

CGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cognition Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGTX shares.
View CGTX analyst ratings
or view top-rated stocks.

What is Cognition Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1-year target prices for Cognition Therapeutics' stock. Their CGTX share price targets range from $6.00 to $9.00. On average, they anticipate the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for CGTX
or view top-rated stocks among Wall Street analysts.

How have CGTX shares performed in 2024?

Cognition Therapeutics' stock was trading at $1.85 on January 1st, 2024. Since then, CGTX shares have decreased by 2.7% and is now trading at $1.80.
View the best growth stocks for 2024 here
.

When is Cognition Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CGTX earnings forecast
.

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its quarterly earnings data on Tuesday, November, 16th. The company reported ($8.12) EPS for the quarter, missing the consensus estimate of ($0.57) by $7.55.

When did Cognition Therapeutics IPO?

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.

Who are Cognition Therapeutics' major shareholders?

Cognition Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Pathstone Holdings LLC (6.87%), Vanguard Group Inc. (2.25%), Vanguard Group Inc. (2.25%), Kestra Advisory Services LLC (0.68%), Mercer Global Advisors Inc. ADV (0.41%) and Twin Focus Capital Partners LLC (0.29%). Insiders that own company stock include Ellen B Richstone, Lisa Ricciardi and Peggy Wallace.
View institutional ownership trends
.

How do I buy shares of Cognition Therapeutics?

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners